Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mining the microbiota for microbial and metabolite-based immunotherapies

Abstract

Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Identifying causal host–microbiota relationships.
Fig. 2: Anti-inflammatory and pro-inflammatory effects of the microbiota.
Fig. 3: Immunomodulation by the microbiota.
Fig. 4: Rational design of microbial therapeutics.

References

  1. Wampach, L. et al. Colonization and succession within the human gut microbiome by archaea, bacteria, and microeukaryotes during the first year of life. Front. Microbiol. 8, 738 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012). Shows the enormous heterogeneity in phylogenetic composition of healthy human microbiota and relative stability of metabolic pathways.

    Article  CAS  Google Scholar 

  3. Round, J. L. & Palm, N. W. Causal effects of the microbiota on immune-mediated diseases. Sci. Immunol. 3, eaao1603 (2018).

    Article  PubMed  Google Scholar 

  4. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219–232 (2017).

    Article  CAS  PubMed  Google Scholar 

  7. Olesen, S. W. & Alm, E. J. Dysbiosis is not an answer. Nat. Microbiol. 1, 16228 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780–13785 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292–298 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wen, L. et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455, 1109–1113 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, 1245 (2012).

    Article  PubMed  CAS  Google Scholar 

  13. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).

    Article  CAS  PubMed  Google Scholar 

  14. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

    Article  PubMed  Google Scholar 

  15. Turnbaugh, P. J. & Gordon, J. I. An Invitation to the marriage of metagenomics and metabolomics. Cell 134, 708–713 (2008).

    Article  CAS  PubMed  Google Scholar 

  16. Gilbert, J. A. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103 (2016).

    Article  CAS  PubMed  Google Scholar 

  17. Blumberg, R. & Powrie, F. Microbiota, disease, and back to health: a metastable journey. Sci. Transl Med. 4, 137rv7 (2012).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Weinstock, G. M. Genomic approaches to studying the human microbiota. Nature 489, 250–256 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, stability and resilience of the human gut microbiota. Nature 489, 220–230 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Surana, N. K. & Kasper, D. L. Moving beyond microbiome-wide associations to causal microbe identification. Nature 552, 244 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fischbach, M. A. Microbiome: focus on causation and mechanism. Cell 174, 785–790 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Postler, T. S. & Ghosh, S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab. 26, 110–130 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Browne, H. P. et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533, 543–546 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lagier, J.-C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 16203 (2016).

    Article  CAS  PubMed  Google Scholar 

  25. Lagier, J.-C. et al. Culturing the human microbiota and culturomics. Nat. Rev. Microbiol. 16, 540–550 (2018).

    Article  CAS  PubMed  Google Scholar 

  26. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698–3703 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).

    Article  CAS  PubMed  Google Scholar 

  28. Cammarota, G., Ianiro, G. & Gasbarrini, A. Fecal microbiota transplantation for the treatment of clostridium difficile infection: a systematic review. J. Clin. Gastroenterol. 48, 693–702 (2014).

    Article  PubMed  Google Scholar 

  29. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013). This study highlights the striking efficacy of FMT for treating CDI.

    Article  PubMed  CAS  Google Scholar 

  30. Smillie, C. S. et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229–240 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Li, S. S. et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352, 586–589 (2016).

    Article  CAS  PubMed  Google Scholar 

  32. Bojanova, D. P. & Bordenstein, S. R. Fecal transplants: what is being transferred? PLOS Biol. 14, e1002503 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Ott, S. J. et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 152, 799–811 (2017).

    Article  PubMed  Google Scholar 

  34. Gerding, D. N. et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial. JAMA 313, 1719–1727 (2015).

    Article  PubMed  Google Scholar 

  35. Ng, S. C. et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 38, 854–863 (2013).

    Article  CAS  PubMed  Google Scholar 

  36. Rossen, N. G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110–118 (2015).

    Article  PubMed  Google Scholar 

  37. Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109 (2015).

    Article  PubMed  Google Scholar 

  38. Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).

    Article  PubMed  Google Scholar 

  39. Kakihana, K. et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood 128, 2083–2088 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Van Lier, Y. F. et al. Fecal microbiota transplantation as safe and successful therapy for intestinal graft-versus-host disease. Blood 130, 1986 (2017).

    Google Scholar 

  41. Doki, N. et al. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 96, 1517–1523 (2017).

    Article  CAS  PubMed  Google Scholar 

  42. Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916 (2012).

    Article  CAS  PubMed  Google Scholar 

  43. Kang, D. W. et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5, 10 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Khanna, S. et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214, 173–181 (2016).

    Article  PubMed  Google Scholar 

  45. Sherman, R. E., Li, J., Shapley, S., Robb, M. & Woodcock, J. Expediting drug development — the FDA’s new “breakthrough therapy” designation. N. Engl. J. Med. 369, 1877–1880 (2013).

    Article  CAS  PubMed  Google Scholar 

  46. Mullard, A. Leading microbiome-based therapeutic falters in phase II trial. Nat. Rev. Drug Discov. 15, 595 (2016).

    PubMed  Google Scholar 

  47. Mills, J. P., Rao, K. & Young, V. B. Probiotics for prevention of Clostridium difficile infection. Curr. Opin. Gastroenterol. 34, 3–10 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Lagier, J.-C., Cadoret, F. & Raoult, D. Critical microbiological view of SER-109. J. Infect. Dis. 215, 161–162 (2017).

    Article  PubMed  Google Scholar 

  49. Ratner, M. Seres’s pioneering microbiome drug fails mid-stage trial. Nat. Biotechnol. 34, 1004–1005 (2016).

    Article  CAS  PubMed  Google Scholar 

  50. Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015). This study shows that C. scindens protects against CDI via production of secondary bile acids.

    Article  CAS  PubMed  Google Scholar 

  51. Sorg, J. A. & Sonenshein, A. L. Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190, 2505–2512 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sorg, J. A. & Sonenshein, A. L. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192, 4983–4990 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Thanissery, R., Winston, J. A. & Theriot, C. M. Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. Anaerobe 45, 86–100 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Baktash, A. et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections. Front. Microbiol. 9, 1242 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  55. Theriot, C. M. & Young, V. B. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu. Rev. Microbiol. 69, 445–461 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Weingarden, A. R. et al. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J. Clin. Gastroenterol. 50, 624–630 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Battaglioli, E. J. et al. Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. Sci. Transl Med. 10, eaam7019 (2018).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Ng, K. M. et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502, 96–99 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Caballero, S. et al. Distinct but spatially overlapping intestinal niches for vancomycin-resistant Enterococcus faecium and carbapenem-resistant Klebsiella pneumoniae. PLOS Pathog. 11, e1005132 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Caballero, S. et al. Cooperating commensals restore colonization resistance to vancomycin-resistant Enterococcus faecium. Cell Host Microbe 21, 592–602 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sorbara, M. T. et al. Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification. J. Exp. Med. 216, 84–98 (2018).

    Article  PubMed  CAS  Google Scholar 

  62. Seed, P. C. The human mycobiome. Cold Spring Harb. Perspect. Med. 5, a019810 (2014).

    Article  PubMed  CAS  Google Scholar 

  63. Nash, A. K. et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 5, 153 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  64. Kernbauer, E., Ding, Y. & Cadwell, K. An enteric virus can replace the beneficial function of commensal bacteria. Nature 516, 94–98 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Cadwell, K. The virome in host health and disease. Immunity 42, 805–813 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Manrique, P. et al. Healthy human gut phageome. Proc. Natl Acad. Sci. USA 113, 10400–10405 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Chudnovskiy, A. et al. Host-protozoan interactions protect from mucosal infections through activation of the inflammasome. Cell 167, 444–456 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Lukeš, J., Stensvold, C. R., Jirků-Pomajbíková, K. & Wegener Parfrey, L. Are human intestinal eukaryotes beneficial or commensals? PLOS Pathog. 11, e1005039 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Ramanan, D. et al. Helminth infection promotes colonization resistance via type 2 immunity. Science 352, 608–612 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Gause, W. C. & Maizels, R. M. Macrobiota - helminths as active participants and partners of the microbiota in host intestinal homeostasis. Curr. Opin. Microbiol. 32, 14–18 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sczesnak, A. et al. The genome of Th17 cell-inducing segmented filamentous bacteria reveals extensive auxotrophy and adaptations to the intestinal environment. Cell Host Microbe 10, 260–272 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Prakash, T. et al. Complete genome sequences of rat and mouse segmented filamentous bacteria, a potent inducer of Th17 cell differentiation. Cell Host Microbe 10, 273–284 (2011).

    Article  CAS  PubMed  Google Scholar 

  73. Schnupf, P. et al. Growth and host interaction of mouse segmented filamentous bacteria in vitro. Nature 520, 99–103 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Tannock, G. W., Miller, J. R. & Savage, D. C. Host specificity of filamentous, segmental microorganisms adherent to the small bowel epithelium in mice and rats. Appl. Environ. Microbiol. 47, 441–442 (1984).

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Klaasen, H. L. B. M. et al. Intestinal, segmented, filamentous bacteria in a wide range of vertebrate species. Lab. Anim. 27, 141–150 (1993).

    Article  CAS  PubMed  Google Scholar 

  76. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009). This study identifies the murine commensal SFB as a potent inducer of T H 17 cells.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Gaboriau-Routhiau, V. et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31, 677–689 (2009).

    Article  CAS  PubMed  Google Scholar 

  78. Talham, G. L., Jiang, H. Q., Bos, N. A. & Cebra, J. J. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect. Immun. 67, 1992–2000 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Lécuyer, E. et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. Immunity 40, 608–620 (2014).

    Article  CAS  PubMed  Google Scholar 

  80. Umesaki, Y., Okada, Y., Matsumoto, S., Imaoka, A. & Setoyama, H. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol. Immunol. 39, 555–562 (1995).

    Article  CAS  PubMed  Google Scholar 

  81. Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013). Used a gnotobiotic pipeline to identify a consortium of 17 human commensals that induce T reg cells.

    Article  CAS  PubMed  Google Scholar 

  82. Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019). Identified a consortium of 11 human commensals that induce IFNγ + CD8 + T cells.

    Article  CAS  Google Scholar 

  83. Palm, N. W. et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158, 1000–1010 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Kau, A. L. et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci. Transl Med. 7, 276ra24 (2015). References 83 and 84 described IgA-seq and its use in identifying microorganisms associated with health and disease.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. D’Auria, G. et al. Active and secreted IgA-coated bacterial fractions from the human gut reveal an under-represented microbiota core. Sci. Rep. 3, 3515 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  86. Wilmore, J. R. et al. Commensal microbes induce serum IgA responses that protect against polymicrobial sepsis. Cell Host Microbe 23, 302–311 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Dodd, D. et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551, 648–652 (2017). This study elucidated the effects of a C. sporogenes metabolic pathway on host physiology.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Guo, C. J. et al. Depletion of microbiome-derived molecules in the host using Clostridium genetics. Preprint at bioRxiv. https://doi.org/10.1101/401489 (2018).

    Article  Google Scholar 

  89. Lim, B., Zimmermann, M., Barry, N. A. & Goodman, A. L. Engineered regulatory systems modulate gene expression of human commensals in the gut. Cell 169, 547–558 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).

    Article  CAS  PubMed  Google Scholar 

  91. Atarashi, K. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015). Showed that epithelial adhesion by SFB promotes T H 17 cell induction and identified 20 microorganisms from humans that induce T H 17 cells.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Vedanta Biosciences. Pipeline. vadantabio https://www.vedantabio.com/pipeline (2019).

  93. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009). Highlights the stability of metabolic pathways across phylogenetically diverse microbiotas.

    Article  CAS  PubMed  Google Scholar 

  94. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 550, 61–66 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Abubucker, S. et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLOS Comput. Biol. 8, 1002358 (2012).

    Article  CAS  Google Scholar 

  96. Shimizu, H., Yisireyili, M., Higashiyama, Y., Nishijima, F. & Niwa, T. Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-κB and p53 in proximal tubular cells. Life Sci. 92, 143–148 (2013).

    Article  CAS  PubMed  Google Scholar 

  97. Shimizu, H. et al. Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-κB, p53, ERK, and JNK in proximal tubular cells. Life Sci. 90, 525–530 (2012).

    Article  CAS  PubMed  Google Scholar 

  98. Devlin, A. S. et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe 20, 709–715 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Williams, B. B. et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16, 495–503 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Bhattarai, Y. et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe 23, 775–785 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Bäumler, A. J. & Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535, 85–93 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Spiga, L. et al. An oxidative central metabolism enables Salmonella to utilize microbiota-derived succinate. Cell Host Microbe 22, 291–301 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Ferreyra, J. A. et al. Gut microbiota-produced succinate promotes C. Difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16, 770–777 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Curtis, M. M. et al. The gut commensal bacteroides thetaiotaomicron exacerbates enteric infection through modification of the metabolic landscape. Cell Host Microbe 16, 759–769 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Fukuda, S. et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543–549 (2011).

    Article  CAS  PubMed  Google Scholar 

  106. Kamada, N. et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science 336, 1325–1329 (2012). References 58, 105 and 106 show that the microbiota can affect susceptibility to enteropathogenic infections by producing or consuming metabolites.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Knoop, K. A., Miller, M. J. & Newberry, R. D. Transepithelial antigen delivery in the small intestine: different paths, different outcomes. Curr. Opin. Gastroenterol. 29, 112–118 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Geva-Zatorsky, N. et al. In vivo imaging and tracking of host–microbiota interactions via metabolic labeling of gut anaerobic bacteria. Nat. Med. 21, 1091–1100 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Hudak, J. E., Alvarez, D., Skelly, A., von Andrian, U. H. & Kasper, D. L. Illuminating vital surface molecules of symbionts in health and disease. Nat. Microbiol. 2, 17099 (2017). References 108 and 109 used a metabolic-labelling platform to tag and track surface molecules on commensal bacteria in vivo.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Mazmanian, S. K., Cui, H. L., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).

    Article  CAS  PubMed  Google Scholar 

  111. Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008). References 110 and 111 showed that the commensal-derived carbohydrate PSA induces T reg cells and IL-10.

    Article  CAS  PubMed  Google Scholar 

  112. Round, J. L. & Mazmanian, S. K. Inducible Foxp3+regulatory T cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl Acad. Sci. USA 11, 79–80 (2010).

    Google Scholar 

  113. Dasgupta, S., Erturk-Hasdemir, D., Ochoa-Reparaz, J., Reinecker, H. C. & Kasper, D. L. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 15, 413–423 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Round, J. L. et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974–977 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Shen, Y. et al. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 12, 509–520 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Chu, H. et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 352, 1116–1120 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Verma, R. et al. Cell surface polysaccharides of Bifidobacterium bifidum induce the generation of Foxp3+regulatory T cells. Sci. Immunol. 3, eaat6975 (2018).

    Article  PubMed  Google Scholar 

  118. Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341 (2011).

    Article  CAS  PubMed  Google Scholar 

  119. Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. Nature 504, 451–455 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).

    Article  CAS  PubMed  Google Scholar 

  121. Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013). References 119–121 provide mechanistic insight into how commensal-derived SCFAs affect host immunity.

    Article  CAS  PubMed  Google Scholar 

  122. Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Macia, L. et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).

    Article  CAS  PubMed  Google Scholar 

  124. Fujiwara, H. et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat. Commun. 9, 3674 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Zhou, L. et al. TGF-Β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453, 236–240 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Sefik, E. et al. Individual intestinal symbionts induce a distinct population of ROR+regulatory T cells. Science 349, 993–997 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Ohnmacht, C. et al. The microbiota regulates type 2 immunity through RORγt+ T cells. Science 349, 989–993 (2015). References 126 and 127 show how the microbiota affects intestinal RORγt + T reg cells.

    Article  CAS  PubMed  Google Scholar 

  128. Xu, M. et al. C-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554, 373–377 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Chai, J. N. et al. Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation. Sci. Immunol. 2, eaal5068 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  130. Sano, T. et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell 163, 381–393 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Tan, T. G. et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc. Natl Acad. Sci. USA 113, E8141–E8150 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Yang, Y. et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510, 152–156 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Hall, A. B. et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 9, 103 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815–827 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  136. Sakaguchi, S., Takahashi, T., Hata, H., Nomura, T. & Sakaguchi, N. SKG mice, a new genetic model of rheumatoid arthritis. Arthritis Res. Ther. 5, 10 (2003).

    Article  PubMed Central  Google Scholar 

  137. Maeda, Y. et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol. 68, 2646–2661 (2016).

    Article  CAS  PubMed  Google Scholar 

  138. Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory T cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 108, 4615–4622 (2011).

    Article  CAS  PubMed  Google Scholar 

  139. Wilck, N. et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature 551, 585–589 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Mangan, P. R. et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231–234 (2006).

    Article  CAS  PubMed  Google Scholar 

  141. Godinez, I. et al. Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype typhimurium in the intestine. Infect. Immun. 77, 387–398 (2009).

    Article  CAS  PubMed  Google Scholar 

  142. Happel, K. I. et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202, 761–769 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358, 162–169 (2017). Shows that members of the oral microbiota can colonize the gut and cause intestinal inflammation.

    Article  CAS  Google Scholar 

  144. Nordmann, P., Cuzon, G. & Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9, 228–236 (2009).

    Article  CAS  PubMed  Google Scholar 

  145. Bell, B. et al. Antibiotic Resistance Threats in the United States (Centers for Disease Control and Prevention, 2013).

  146. Hampton, T. Report reveals scope of US antibiotic resistance threat. JAMA 310, 1661–1663 (2013).

    Article  CAS  PubMed  Google Scholar 

  147. Chassaing, B., Koren, O., Carvalho, F. A., Ley, R. E. & Gewirtz, A. T. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut 63, 1069–1080 (2014).

    Article  CAS  PubMed  Google Scholar 

  148. Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 127, 412–421 (2004).

    Article  PubMed  Google Scholar 

  149. Martin, H. M. et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology 127, 80–93 (2004).

    Article  CAS  PubMed  Google Scholar 

  150. Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 487, 104–108 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Olivares-Villagómez, D. & Van Kaer, L. Intestinal intraepithelial lymphocytes: sentinels of the mucosal barrier. Trends Immunol. 39, 264–275 (2018).

    Article  PubMed  CAS  Google Scholar 

  152. Gutiérrez-Vázquez, C. & Quintana, F. J. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48, 19–33 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  153. Li, Y. et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147, 629–640 (2011).

    Article  CAS  PubMed  Google Scholar 

  154. Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+T cells. Science 357, 806–810 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Sujino, T. et al. Tissue adaptation of regulatory and intraepithelial CD4+T cells controls gut inflammation. Science 352, 1581–1586 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Mucida, D. et al. Transcriptional reprogramming of mature CD4+helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat. Immunol. 14, 281–289 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Reis, B. S., Rogoz, A., Costa-Pinto, F. A., Taniuchi, I. & Mucida, D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4+ T cell immunity. Nat. Immunol. 14, 271–280 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Reis, B. S., Hoytema van Konijnenburg, D. P., Grivennikov, S. I. & Mucida, D. Transcription factor T-bet regulates intraepithelial lymphocyte functional maturation. Immunity 41, 244–256 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Steenholt, J. V. et al. The composition of T cell subtypes in duodenal biopsies are altered in coeliac disease patients. PLOS ONE 12, e0170270 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  160. Carton, J., Byrne, B., Madrigal-Estebas, L., O’Donoghue, D. P. & O’Farrelly, C. CD4+CD8+human small intestinal T cells are decreased in coeliac patients, with CD8 expression downregulated on intra-epithelial T cells in the active disease. Eur. J. Gastroenterol. Hepatol. 16, 961–968 (2004).

    Article  PubMed  Google Scholar 

  161. Godfrey, D. I., Stankovic, S. & Baxter, A. G. Raising the NKT cell family. Nat. Immunol. 11, 197–206 (2010).

    Article  CAS  PubMed  Google Scholar 

  162. Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336, 489–493 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. An, D. et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156, 123–133 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Wieland Brown, L. C. et al. Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLOS Biol. 11, e1001610 (2013).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  165. Ma, C. et al. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  166. Iyer, S. S. et al. Dietary and microbial oxazoles induce intestinal inflammation by modulating aryl hydrocarbon receptor responses. Cell 173, 1123–1134 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Metelev, M. V. & Ghilarov, D. A. Structure, function, and biosynthesis of thiazole/oxazole-modified microcins. Mol. Biol. 48, 29–45 (2014).

    Article  CAS  Google Scholar 

  168. Xiao, X. & Cai, J. Mucosal-associated invariant T cells: New insights into antigen recognition and activation. Front. Immunol. 8, 1540 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  169. Gold, M. C. et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLOS Biol. 8, e1000407 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  170. Georgel, P., Radosavljevic, M., Macquin, C. & Bahram, S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol. Immunol. 48, 769–775 (2011).

    Article  CAS  PubMed  Google Scholar 

  171. Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164–169 (2003).

    Article  CAS  PubMed  Google Scholar 

  172. Le Bourhis, L., Mburu, Y. K. & Lantz, O. MAIT cells, surveyors of a new class of antigen: development and functions. Curr. Opin. Immunol. 25, 174–180 (2013).

    Article  PubMed  CAS  Google Scholar 

  173. Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012).

    Article  CAS  PubMed  Google Scholar 

  174. Corbett, A. J. et al. T cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509, 361–365 (2014).

    Article  CAS  PubMed  Google Scholar 

  175. Chen, Z. et al. Mucosal-associated invariant T cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. Mucosal Immunol. 10, 58–68 (2017).

    Article  CAS  PubMed  Google Scholar 

  176. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

    Article  CAS  PubMed  Google Scholar 

  177. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). References 176–178 show that gut commensals affect responses to immune checkpoint blockade therapy in patients with cancer.

    Article  CAS  PubMed  Google Scholar 

  179. Uchimura, Y. et al. Antibodies set boundaries limiting microbial metabolite penetration and the resultant mammalian host response. Immunity 49, 545–559 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Donaldson, G. P. et al. Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360, 795–800 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  181. Bunker, J. J. et al. Natural polyreactive IgA antibodies coat the intestinal microbiota. Science 358, eaan6619 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  182. Kim, M., Qie, Y., Park, J. & Kim, C. H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe 20, 202–214 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. McLoughlin, K., Schluter, J., Rakoff-Nahoum, S., Smith, A. L. & Foster, K. R. Host selection of microbiota via differential adhesion. Cell Host Microbe 19, 550–559 (2016).

    Article  CAS  PubMed  Google Scholar 

  184. Coombes, J. L. & Powrie, F. Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 8, 435–446 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Coombes, J. L. et al. A functionally specialized population of mucosal CD103+DCs induces Foxp3+regulatory T cells via a TGF-β– and retinoic acid–dependent mechanism. J. Exp. Med. 204, 1757–1764 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Sun, C.-M. et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775–1785 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Travis, M. A. et al. Loss of integrin αvβ8 on dendritic cells causes autoimmunity and colitis in mice. Nature 449, 361–365 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Jaensson-Gyllenbäck, E. et al. Bile retinoids imprint intestinal CD103 + dendritic cells with the ability to generate gut-tropic T cells. Mucosal Immunol. 4, 438–447 (2011).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  189. Yokota, A. et al. GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int. Immunol. 21, 361–377 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527–538 (2004).

    Article  CAS  PubMed  Google Scholar 

  191. Tanoue, T., Atarashi, K. & Honda, K. Development and maintenance of intestinal regulatory T cells. Nat. Rev. Immunol. 16, 295–309 (2016).

    Article  CAS  PubMed  Google Scholar 

  192. Xu, L. et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33, 313–325 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Zeng, R. et al. Retinoic acid regulates the development of a gut-homing precursor for intestinal dendritic cells. Mucosal Immunol. 6, 847–856 (2013).

    Article  CAS  PubMed  Google Scholar 

  194. Zeng, R., Bscheider, M., Lahl, K., Lee, M. & Butcher, E. C. Generation and transcriptional programming of intestinal dendritic cells: essential role of retinoic acid. Mucosal Immunol. 9, 183–193 (2016).

    Article  CAS  PubMed  Google Scholar 

  195. Konieczna, P. et al. Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms. PLOS ONE 8, e62617 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab. 22, 971–982 (2015).

    Article  CAS  PubMed  Google Scholar 

  197. Rubic, T. et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat. Immunol. 9, 1261–1269 (2008).

    Article  CAS  PubMed  Google Scholar 

  198. Wu, W. et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol. 10, 946–956 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  199. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

    Article  CAS  PubMed  Google Scholar 

  200. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774 (2004).

    Article  CAS  PubMed  Google Scholar 

  201. Puccetti, P. & Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat. Rev. Immunol. 7, 817–823 (2007).

    Article  CAS  PubMed  Google Scholar 

  202. Kim, M. et al. Critical role for the microbiota in CX3CR1+intestinal mononuclear phagocyte regulation of intestinal T cell responses. Immunity 49, 151–163 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Diehl, G. E. et al. Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX3CR1-hi cells. Nature 494, 116–120 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Panea, C. et al. Intestinal monocyte-derived macrophages control commensal-specific Th17 responses. Cell Rep. 12, 1314–1324 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl Acad. Sci. USA 111, 2247–2252 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  206. Mann, E. R. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl Med. 10, 4755 (2018).

    Article  CAS  Google Scholar 

  207. Ji, J. et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci. Rep. 6, 24838 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Steed, A. L. et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357, 498–502 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Karst, S. M. The influence of commensal bacteria on infection with enteric viruses. Nat. Rev. Microbiol. 14, 197–204 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Kuss, S. K. et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334, 249–252 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Claesen, J. & Fischbach, M. A. Synthetic microbes as drug delivery systems. ACS Synth. Biol. 4, 358–364 (2015).

    Article  CAS  PubMed  Google Scholar 

  212. Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16–34 (2011).

    Article  CAS  PubMed  Google Scholar 

  213. Krawczyk, C. M. et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742–4749 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Kelly, B. & O’Neill, L. A. J. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 25, 771–784 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  215. Symbiotix Biotherapies. Pipeline. symbiotix-bio http://symbiotix-bio.com/research-and-development/pipeline/ (2019).

  216. Sonnenburg, J. L. & Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Suez, J. & Elinav, E. The path towards microbiome-based metabolite treatment. Nat. Microbiol. 2, 17075 (2017).

    Article  CAS  PubMed  Google Scholar 

  218. Stein, R. R. et al. Computer-guided design of optimal microbial consortia for immune system modulation. eLife 7, e30916 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  219. Tramontano, M. et al. Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies. Nat. Microbiol. 3, 514–522 (2018).

    Article  CAS  PubMed  Google Scholar 

  220. Maldonado-Gómez, M. X. et al. Stable engraftment of bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20, 515–526 (2016).

    Article  PubMed  CAS  Google Scholar 

  221. Shepherd, E. S., Deloache, W. C., Pruss, K. M., Whitaker, W. R. & Sonnenburg, J. L. An exclusive metabolic niche enables strain engraftment in the gut microbiota. Nature 557, 434–438 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  222. Gurry, T. et al. Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. Sci. Rep. 8, 12699 (2017).

    Article  CAS  Google Scholar 

  223. Panigrahi, P. et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 548, 407–412 (2017). This study shows that a synbiotic consisting of L. plantarum and fructo-oligosaccharide protects infants against sepsis.

    Article  CAS  PubMed  Google Scholar 

  224. Panigrahi, P. et al. Long-term colonization of a lactobacillus plantarum synbiotic preparation in the neonatal gut. J. Pediatr. Gastroenterol. Nutr. 47, 45–53 (2008).

    Article  PubMed  Google Scholar 

  225. Goodman, A. L. et al. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc. Natl Acad. Sci. USA 108, 6252–6257 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  226. Litvak, Y., Byndloss, M. X. & Bäumler, A. J. Colonocyte metabolism shapes the gut microbiota. Science 362, eaat9076 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  227. Byndloss, M. X., Pernitzsch, S. R. & Bäumler, A. J. Healthy hosts rule within: ecological forces shaping the gut microbiota. Mucosal Immunol. 11, 1299–1305 (2018).

    Article  CAS  PubMed  Google Scholar 

  228. Byndloss, M. X. et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357, 570–575 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Litvak, Y., Byndloss, M. X., Tsolis, R. M. & Bäumler, A. J. Dysbiotic proteobacteria expansion: a microbial signature of epithelial dysfunction. Curr. Opin. Microbiol. 39, 1–6 (2017).

    Article  CAS  PubMed  Google Scholar 

  230. Tang, C. et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat. Immunol. 19, 755–765 (2018).

    Article  CAS  PubMed  Google Scholar 

  231. Cullen, T. W. et al. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347, 170–175 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  232. Seregin, S. S. et al. NLRP6 protects Il10−/−mice from colitis by limiting colonization of akkermansia muciniphila. Cell Rep. 19, 733–745 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Png, C. W. et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 105, 2420–2428 (2010).

    Article  CAS  PubMed  Google Scholar 

  234. Chelakkot, C. et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp. Mol. Med. 50, e450 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  235. Schneeberger, M. et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 5, 16643 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  236. Hryckowian, A. J. et al. Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model. Nat. Microbiol. 3, 662–669 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  237. Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).

    Article  CAS  PubMed  Google Scholar 

  238. Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 (2006).

    Article  CAS  PubMed  Google Scholar 

  239. Álvarez, B. & Fernández, L. Á. Sustainable therapies by engineered bacteria. Microb. Biotechnol. 10, 1057–1061 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  240. Duan, F. & March, J. C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260–11264 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  241. Silva, A. J. & Benitez, J. A. Vibrio cholerae biofilms and cholera pathogenesis. PLOS Negl. Trop. Dis. 10, e0004330 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  242. Hsiao, A. et al. Members of the human gut microbiota involved in recovery from Vibrio cholerae infection. Nature 515, 423–426 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Saeidi, N. et al. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol. Syst. Biol. 7, 521 (2011).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  244. Hwang, I. Y. et al. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 8, 15028 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  245. Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).

    Article  PubMed  CAS  Google Scholar 

  246. Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M. & Marchesi, J. R. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Natl Acad. Sci. USA 105, 13580–13585 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Kitahara, M., Takamine, F., Imamura, T. & Benno, Y. Assignment of eubacterium sp. VPI 12708 and related strains with high bile acid 7α-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 50, 971–978 (2000).

    Article  CAS  PubMed  Google Scholar 

  248. Kitahara, M., Takamine, F., Imamura, T. & Benno, Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7α-dehydroxylating activity. Int. J. Syst. Evol. Microbiol. 51, 39–44 (2001).

    Article  CAS  PubMed  Google Scholar 

  249. Ridlon, J. M., Kang, D.-J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259 (2006).

    Article  CAS  PubMed  Google Scholar 

  250. Ridlon, J., Kang, D., Hylemon, P. & Bajaj, J. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332–338 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  251. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F. & Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147–191 (2009).

    Article  CAS  PubMed  Google Scholar 

  252. Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731–744 (2000).

    Article  CAS  PubMed  Google Scholar 

  253. Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251–6261 (2009).

    Article  CAS  PubMed  Google Scholar 

  254. Chen, X., Lou, G., Meng, Z. & Huang, W. TGR5: a novel target for weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011, 853501 (2011).

    PubMed  PubMed Central  Google Scholar 

  255. Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714–719 (2002).

    Article  CAS  PubMed  Google Scholar 

  256. Haselow, K. et al. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J. Leukoc. Biol. 94, 1253–1264 (2013).

    Article  PubMed  CAS  Google Scholar 

  257. Keitel, V., Donner, M., Winandy, S., Kubitz, R. & Häussinger, D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372, 78–84 (2008).

    Article  CAS  PubMed  Google Scholar 

  258. Perino, A. et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J. Clin. Invest. 124, 5424–5436 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  259. Pols, T. W. H. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14, 747–757 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  260. Pols, T. W. H. et al. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. PLOS ONE 12, e0176715 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  261. Smith, K., McCoy, K. D. & Macpherson, A. J. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin. Immunol. 19, 59–69 (2007).

    Article  CAS  PubMed  Google Scholar 

  262. Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313–323 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  263. Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149, 1578–1593 (2012). This study shows that a host-specific microbiota is necessary for immunomaturation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  264. Zhang, L. et al. Environmental spread of microbes impacts the development of metabolic phenotypes in mice transplanted with microbial communities from humans. ISME J. 11, 676–690 (2017).

    Article  PubMed  Google Scholar 

  265. Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).

    Article  PubMed  CAS  Google Scholar 

  266. Turnbaugh, P. J. et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl Med. 1, 6ra14 (2009).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  267. Hugenholtz, F. & De Vos, W. M. Mouse models for human intestinal microbiota research: a critical evaluation. Cell. Mol. Life Sci. 75, 149–160 (2018).

    Article  CAS  PubMed  Google Scholar 

  268. Takahashi, S. et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J. Lipid Res. 57, 2130–2137 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  269. Nguyen, T. L. A., Vieira-Silva, S., Liston, A. & Raes, J. How informative is the mouse for human gut microbiota research? Dis. Model. Mech. 8, 1–16 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  270. Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl Acad. Sci. USA 113, E7–E15 (2016).

    Article  CAS  PubMed  Google Scholar 

  271. Shah, P. et al. A microfluidics-based in vitro model of the gastrointestinal human-microbe interface. Nat. Commun. 7, 11535 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  272. Turnbaugh, P. J., Bäckhed, F., Fulton, L. & Gordon, J. I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  273. Bloom, S. M. et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9, 390–403 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  274. Stefka, A. T. et al. Commensal bacteria protect against food allergen sensitization. Proc. Natl Acad. Sci. USA 111, 13145–13150 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  275. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  276. Derrien, M., Vaughan, E. E., Plugge, C. M. & de Vos, W. M. Akkermansia municiphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 54, 1469–1476 (2004).

    Article  CAS  PubMed  Google Scholar 

  277. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066–9071 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  278. Ottman, N. et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLOS ONE 12, e0173004 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  279. van den Abbeele, P. et al. Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ. Microbiol. 13, 2667–2680 (2011).

    Article  PubMed  CAS  Google Scholar 

  280. Chia, L. W. et al. Deciphering the trophic interaction between Akkermansia muciniphila and the butyrogenic gut commensal Anaerostipes caccae using a metatranscriptomic approach. Antonie Van Leeuwenhoek 111, 859–873 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  281. Ijssennagger, N. et al. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc. Natl Acad. Sci. USA 112, 10038–10043 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  282. Ganesh, B. P., Klopfleisch, R., Loh, G. & Blaut, M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella typhimurium-infected gnotobiotic mice. PLOS ONE 8, e74963 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  283. Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339–1353 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  284. Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255–1269 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Japan Agency for Medical Research and Development (AMED) LEAP under grant number JP18gm0010003, the Takeda Science Foundation, the Mitsukoshi Health and Welfare Foundation (K.H.) and Grant-in-Aid for Japan Society for the Promotion of Science (JSPS) Fellows (18F18104) (S.K.).

Reviewer information

Nature Reviews Immunology thanks N. Cerf-Bensussan, L. O’Neill and P. Turnbaugh for their contribution to the peer review of this work.

Author information

Authors and Affiliations

Authors

Contributions

All authors were involved in discussing the content and writing this article. A.N.S., Y.S. and S.K. were involved in researching data for the article. K.H. and A.N.S. contributed to the review and editing of the article before submission.

Corresponding author

Correspondence to Kenya Honda.

Ethics declarations

Competing interests

K.H. is co-founder of and scientific adviser to Vedanta Biosciences since 11 August 2011. The other authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Glossary

Dysbiosis

The perturbation of the homeostatic microbiota composition; associated with a slew of diseases. The ambiguity of this term can encompass increases in pathobionts, decreases in commensals or changes that do not clearly distinguish healthy from unhealthy guts.

Gnotobiotic

Referring to mice that are only colonized by a known, defined set of microorganisms.

Colonization resistance

The mechanism by which certain microorganisms are prevented from colonizing an ecosystem (for example, the gut) by the indigenous microorganisms.

Germ-free (GF) mice

Mice living in sterile conditions, uncolonized by any microorganism.

Muricholic acids

A class of 6-hydroxy bile acids present in mice but not humans.

Beta-diversity

The ecological diversity between environments (for example, gut microbial diversity between different individuals).

M cells

Microfold cells found in Peyer’s patches that transcytose material (including antigen and IgA) across the intestinal epithelium.

Metabolic oligosaccharide engineering

The process of co-opting endogenous bacterial biosynthetic machinery to introduce a synthetic non-natural sugar containing an inert chemical ‘handle’ into surface macromolecules.

Bioorthogonal click chemistry

Any chemical reaction that can occur rapidly and specifically in the complex cellular milieu. Often used in conjunction with metabolic oligosaccharide engineering to functionalize a tagged macromolecule.

Outer membrane vesicles

(OMVs). Vesicles containing periplasm; released into the extracellular space by Gram-negative bacteria.

Aryl hydrocarbon receptor

(AhR). A cytosolic ligand-activated transcription factor that controls the expression of many genes.

Auxotrophic

Relating to auxotrophy; the inability to produce a substance required for growth. Using an auxotrophic bacterial strain enables reversible colonization under experimental conditions.

M2 macrophage phenotype

‘M1’ and ‘M2’ are classifications historically used to define macrophages activated in vitro as pro-inflammatory (when classically activated with IFNγ and lipopolysaccharide) or anti-inflammatory (when alternatively activated with IL-4 or IL-10), respectively. However, in vivo macrophages are highly specialized, transcriptomically dynamic and extremely heterogeneous with regards to their phenotypes and functions, which are continuously shaped by their tissue microenvironment. Therefore, the M1 or M2 classification is too simplistic to explain the true nature of in vivo macrophages, although these terms are still often used to indicate whether the macrophages in question are more pro-inflammatory or anti-inflammatory.

Synbiotic

A therapeutic consisting of probiotics (bacteria) together with prebiotics (nutrients).

Quorum-sensing

The ability to sense population density and respond accordingly at the gene expression level.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Skelly, A.N., Sato, Y., Kearney, S. et al. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol 19, 305–323 (2019). https://doi.org/10.1038/s41577-019-0144-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-019-0144-5

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing